Solid Biosciences reports Q3 2026 results, schedules FDA Type C meeting on SGT-003

Solid Biosciences reported third quarter 2026 financial results and business updates. It has scheduled a Type C meeting with the FDA in late Q4 2026 to discuss preliminary INSPIRE DUCHENNE SGT-003 data and seek guidance on a potential accelerated approval pathway, expecting an update after receiving formal meeting minutes.

Detected & updated continuously · Source: Nebula